Answers are grounded in this paper and cite their sources.
Seizures contributed substantially to the neurologic morbidity of MGs in at least 25% of these patients. The occurrence of seizures at diagnosis was a strong predictor of subsequent seizures, and in many patients, seizures proved to be refractory to standard anticonvulsant therapy. Long-term anticonvulsant toxic side effects are relatively common in patients with MGs. The use of long-term seizure prophylaxis for patients with MGs who are free of seizures at presentation is not clearly beneficial and should be studied in a prospective trial.
No takes yet. Share an insight, caveat, or question.
Moots et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: